Abcam, ab271923, Anti-P Glycoprotein antibody [EPR10363] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal P Glycoprotein antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10363,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab271923 is the carrier-free version of
ab170903
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
P-glycoprotein also known as P-gp MDR1 transporter or ABCB1 is a well-characterized efflux transporter with a molecular mass of approximately 170 kDa. This protein is expressed in various normal tissues such as the liver intestine kidney blood-brain barrier and placenta. It is located on the cell membrane where it functions to expel a wide variety of substrates out of cells using energy derived from ATP hydrolysis. This capability of pumping out toxins and xenobiotics makes P-glycoprotein an important player in cellular detoxification.
Biological function summary
P-glycoprotein acts as a protective mechanism against toxic substances and drugs within the body. It is a member of the ATP-binding cassette (ABC) transporter family which is critical for their ability to transport molecules across membranes. P-glycoprotein is not typically part of a larger protein complex but can interact with other membrane proteins to facilitate its function. Its role in drug metabolism and excretion is vital for maintaining the balance and elimination of harmful substances.
Pathways
P-glycoprotein plays a significant role in the pharmacokinetics of drugs within the body. This transporter is involved in the multi-drug resistance (MDR) pathway which impacts the efficacy of chemotherapeutic agents. P-glycoprotein also interacts with other proteins like CYP3A4 which is involved in the metabolism of many drugs. These interactions affect the concentration and distribution of therapeutic agents contributing to the body's overall drug response.
P-glycoprotein is closely associated with multi-drug resistance in cancer where its overexpression can lead to reduced effectiveness of chemotherapy. It is also implicated in disorders of the central nervous system like epilepsy where it affects drug delivery to the brain. The protein has connections with CYP3A4 in these contexts where both together influence drug metabolism and efficacy complicating treatment regimens and therapeutic outcomes in these conditions.